相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific
Benson Gikanga et al.
BIOCONJUGATE CHEMISTRY (2016)
New developments for antibody-drug conjugate-based therapeutic approaches
Bart E. C. G. de Goeij et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
HER2-targeted antibody drug conjugates for ovarian cancer therapy
Jing Jiang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload
Arnaud C. Tiberghien et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice
Yuanyi Mang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Shahid Ahmed et al.
BREAST CANCER (2015)
HER2 aberrations in cancer: Implications for therapy
Min Yan et al.
CANCER TREATMENT REVIEWS (2014)
Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
John M. Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S. Kung Sutherland et al.
BLOOD (2013)
Antibody-drug conjugates
Rachel S. Zolot et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer
Jonathan G. Drachman et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix
Katrin Hochdoerffer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Kamal S. Saini et al.
BREAST (2011)
Investigational antibody drug conjugates for solid tumors
Puja Sapra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates
SC Jeffrey et al.
BIOCONJUGATE CHEMISTRY (2006)
Dipeptide-based highly potent doxorubicin antibody conjugates
SC Jeffrey et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Update on HER-2 as a target for cancer therapy - Intracellular signaling pathways of ErbB2/HER-2 and family members
MA Olayioye
BREAST CANCER RESEARCH (2001)
Unraveling the role of proteases in cancer
JE Koblinski et al.
CLINICA CHIMICA ACTA (2000)
分享论文
